Clinical bottom line
Neuropsychiatric symptoms (NPS) such as agitation, psychosis, depression, and apathy are highly prevalent in patients with advanced dementia receiving palliative care. Optimal management requires a careful balance between non-pharmacological interventions and judicious use of pharmacologic agents tailored to symptom severity, patient goals, and potential adverse effects. Current evidence supports prioritizing individualized, multidisciplinary approaches with cautious pharmacotherapy reserved for distressing or dangerous symptoms unresponsive to non-drug measures. This approach aims to maximize comfort and quality of life while minimizing medication burden and adverse events.
What the evidence shows
Neuropsychiatric symptoms affect up to 90% of patients with dementia during the disease course and are associated with increased caregiver burden, hospitalization, and mortality (Kales et al., 2016). In advanced stages, these symptoms often intensify and complicate palliative care delivery (Santos Logan Andrade dos et al., 2025).
Non-pharmacological interventions remain first-line and include environmental modification, behavioral strategies, caregiver education, and psychosocial support. These approaches can reduce symptom severity and improve patient and caregiver outcomes without medication-related risks (Santos Logan Andrade dos et al., 2025; Kales et al., 2016).
Pharmacologic treatment is reserved for severe, persistent, or dangerous symptoms such as severe agitation, psychosis, or depression refractory to non-drug measures. Antipsychotics, particularly atypical agents, have demonstrated modest efficacy but carry significant risks including sedation, falls, cerebrovascular events, and mortality (Ballard et al., 2009; Marano et al., 2016). Therefore, their use should be limited, closely monitored, and regularly re-evaluated.
Antidepressants and mood stabilizers may have a role in managing depressive and mood symptoms, though evidence is less robust and requires individualized assessment (Marano et al., 2016). Benzodiazepines are generally discouraged due to risks of sedation, cognitive worsening, and falls but may be considered short-term for acute distress or severe anxiety (Santos Logan Andrade dos et al., 2025).
Palliative care principles emphasize symptom relief aligned with patient goals, often focusing on comfort rather than disease modification. This perspective supports minimizing polypharmacy and prioritizing interventions that enhance quality of life (Santos Logan Andrade dos et al., 2025; Nursing, 2022).
Caveats and uncertainty
High-quality randomized controlled trials specifically addressing neuropsychiatric symptom management in advanced dementia within palliative care settings remain limited. Much evidence derives from broader dementia populations or institutional settings, which may not fully generalize to palliative contexts (Santos Logan Andrade dos et al., 2025).
The heterogeneity of neuropsychiatric symptoms and individual patient variability challenge standardized treatment algorithms. Symptom overlap and fluctuating presentations complicate assessment and response evaluation (Paul et al., 2022).
Pharmacologic treatments carry significant risks, and the balance between benefit and harm is delicate, especially in frail patients with multiple comorbidities. Long-term safety data in palliative populations are sparse (Ballard et al., 2009; Marano et al., 2016).
Caregiver capacity and healthcare resources influence the feasibility and effectiveness of non-pharmacological interventions. Cultural and ethical considerations also impact decision-making around sedation and medication use at end of life (Nursing, 2022).
How this may change practice
Clinicians should adopt a comprehensive, multidisciplinary approach to neuropsychiatric symptoms in advanced dementia, emphasizing thorough assessment, non-pharmacological strategies, and shared decision-making with patients’ families and care teams.
Routine screening for neuropsychiatric symptoms and their impact on patient comfort and caregiver burden can guide timely interventions. Education and support for caregivers are critical components.
Pharmacologic treatments should be reserved for symptoms causing significant distress or safety concerns, initiated at the lowest effective dose, and regularly reviewed for efficacy and adverse effects. Deprescribing should be considered when symptoms improve or goals of care evolve.
Integration of palliative care principles encourages prioritizing comfort and quality of life over aggressive symptom control, aligning management with patient values and prognosis.
Further research is needed to define optimal intervention combinations, dosing strategies, and monitoring protocols tailored to palliative care populations.